Abstract 1711P
Background
Novel SARS-CoV-2 infection has been a severe health problem in Italy since the beginning of March 2020, with around 227,000 confirmed cases on May 18th, 2020. The north-western part of Tuscany has been one of the areas with the highest incidence (342/100,000 inhabitants) and the highest lethality rate (31,2/100,000 inhabitants). The lethality rate was higher in men than women (12.6% vs. 7.4%). People aged 70-79 represented half of this population and the deaths in this subgroup represented 15.9% of all SARS-CoV-2-related deaths. Cancer patients are known to be at higher risk of incidence and complications from SARS-CoV-2. We aimed at analyzing the incidence and the lethality of Sars-CoV-2 in our prostate cancer (PC) patients (pts), in whom hormonal therapy seems to be protective from the first evidences published in the literature.
Methods
We reviewed all the clinical files of PC pts’visits performed from March 1st to April 30th, 2020 in the University Hospital of Pisa. We analyzed the demographic characteristics, the comorbidities, the type of hormonal therapy pts received, the incidence of SARS-CoV-2 and the related lethality rate.
Results
132 pts with PC had face-to-face or telemedicine visits in the considered period. The median age was 76 (range 52-91); 86 (65.15%) pts were 75 or older. The median number of comorbidites was 2 (range 0-6); 112 (84.85%) pts had at least two comorbidities. 115 (87.12%) pts received LHRH analogue in the adjuvant or metastatic setting, 17 (12.88%) pts received LHRH analogue in combination with an anti-androgen. One pt had a confirmed SARS-CoV-2 infection (0.76%), other 2 pts (1.52%) had a clinical and/or radiological suspicion of SARS-CoV2 infection, but no PCR confirmation. One of these three pts (0.76%) died of ARDS (the considered pt had no PCR confirmation of SARS-CoV-2); the patient was 89 years old and had three comorbidities.
Conclusions
In our population, living in a high-incidence area for SARS-CoV2 infection, though being composed by elderly men with a discrete number of comorbidities, the incidence rate was quite low, as well as the lethality rate, corroborating the data published in the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.